Case Studies

Microvision

Today, Microvision is a leader in the development of light scanning technologies for high-resolution display and imaging systems. When this innovative young company came to MDB Capital in 2005, they had a breakthrough proprietary technology, vast potential, and a significant need for capital to propel their company forward.

Working side-by-side with Microvision’s executive team, MDB Capital did more than raise the necessary capital; we helped the company align its business and financial strategies. With the personal involvement of our principals, MDB Capital began by assessing Microvision’s target markets, competing technologies, and industry trends. We quickly understood the company’s core technology and its true value, then helped the company refine its messaging to better position it for investor interest.

Microvision developed and implemented its new direction, growth strategy, leadership team and organizational structure, and crystallized its company message: To be an integral component in every micro-display and imaging product sold.

With this new strategy and message in place, MDB Capital introduced Microvision to select investors through a series of road shows. And in June of 2006, despite challenging market conditions, Microvision completed a critical capital raise of $25.1M in May 2006, followed by a $7.9M offering in November 2006, to move the company toward its goals.

Read Testimonial

“Despite challenging market conditions, Microvision completed an important capital raise of $25.1 M. This transaction was made possible due to the effective management execution by the MDB Capital principals….Throughout the process, MDB showed commendable domain expertise, solid industry contacts and tenacity in completing this transaction….We are very pleased with MDB’s team process and results, and I would highly recommend them to others.”

— Alexander Tokman Microvision President and CEO

Medivation

When Medivation first approached MDB Capital, the start-up company consisted of three employees with access to licensed technology for the treatment of Alzheimer’s Disease. With a promising technology, the company had achieved minimal success in raising the capital it needed to take its innovation to the clinical trial stage.

MDB Capital helped reposition Medivation as a pharmaceutical company that creates value. We successfully crafted and communicated Medivation’s unique business model and strategy, positioning the company as a team of experts with the extensive resources and capabilities to take early-stage medical technologies to Phase III clinical trials — and thus to market. Serving as advisor, we then helped the company locate and recruit high-profile board members and complete a merger with Orion Acquisition Corp II.

The completed reverse merger resulted in financing totaling $142 million. The company’s market value escalated from $10 million to over $100 million in less than 18 months. The strategic merger and capital infusion have allowed Medivation to continue identifying and developing new technologies needed to grow its product pipeline and diversify risk.